141 related articles for article (PubMed ID: 930747)
21. Bromocriptine and dopaminergic function in Huntington disease.
Loeb C; Roccatagliata G; Albano C; Besio G
Neurology; 1979 May; 29(5):730-4. PubMed ID: 155784
[TBL] [Abstract][Full Text] [Related]
22. Determinations of 5-hydroxyindoleacetic acid and homovanillic acid in human CSF with monitoring of probenecid levels in CSF and plasma.
Emanuelsson BM; Widerlöv E; Walléus H; Paalzow LK
Psychopharmacology (Berl); 1987; 92(2):144-9. PubMed ID: 2440072
[TBL] [Abstract][Full Text] [Related]
23. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Przuntek H; Kuhn W
Adv Neurol; 1990; 53():445-9. PubMed ID: 1700583
[No Abstract] [Full Text] [Related]
24. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Przuntek H; Kuhn W; Kraus P
Acta Neurol Scand Suppl; 1989; 126():153-6. PubMed ID: 2482649
[TBL] [Abstract][Full Text] [Related]
25. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Davidson DL; Yates CM; Mawdsley C; Pullar IA; Wilson H
J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1136-41. PubMed ID: 591981
[TBL] [Abstract][Full Text] [Related]
26. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Truelle JL; Chanelet J; Bastard J; Six P; Emile J
Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
[TBL] [Abstract][Full Text] [Related]
27. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
[TBL] [Abstract][Full Text] [Related]
28. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Siirtola T; Sonninen V; Rinne UK
Clin Neurol Neurosurg; 1975; 78(2):77-88. PubMed ID: 1222507
[TBL] [Abstract][Full Text] [Related]
29. Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method.
Vanderheyden JE; Noel G; Mendlewicz J
Neuropsychobiology; 1981; 7(3):137-51. PubMed ID: 6164951
[TBL] [Abstract][Full Text] [Related]
30. Probenecid sensitive pathway of elimination of dopamine and serotonin metabolites in CSF of the rat.
Elghozi JL; Mignot E; Le Quan-Bui KH
J Neural Transm; 1983; 57(1-2):85-94. PubMed ID: 6194256
[TBL] [Abstract][Full Text] [Related]
31. Bromocriptine treatment of depressive disorders. Clinical and biochemical effects.
Nordin C; Siwers B; Bertilsson L
Acta Psychiatr Scand; 1981 Jul; 64(1):25-33. PubMed ID: 6172006
[TBL] [Abstract][Full Text] [Related]
32. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Callaghan N; Fitzpatrick E; O'Mahony JB
Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
[TBL] [Abstract][Full Text] [Related]
33. Tetrahydrobiopterin and Parkinson's disease.
Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Di Paolo T; Bédard P; Daigle M; Boucher R
Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166
[TBL] [Abstract][Full Text] [Related]
35. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Feigenson JS; Sweet RD; McDowell FH
Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
[TBL] [Abstract][Full Text] [Related]
36. [Dopaminergic agonists in Parkinson disease].
Dubois B; Agid Y
Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
[No Abstract] [Full Text] [Related]
37. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
Hutt CS; Snider SR; Fahn S
Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
[TBL] [Abstract][Full Text] [Related]
38. [Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (HIAA) in the CSF after administration of probenecid in Huntington's chorea. Effect of lithium carbonate].
Livrea P; Di Reda L; Ragno G; Germinario L; Papagno G
Riv Neurobiol; 1977; 23(3):149-59. PubMed ID: 154166
[No Abstract] [Full Text] [Related]
39. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
Parkes JD; Debono AG; Marsden CD
J Neurol Neurosurg Psychiatry; 1976 Nov; 39(11):1101-8. PubMed ID: 1036999
[TBL] [Abstract][Full Text] [Related]
40. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
Rinne UK
Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
